

KEYTRUDA[®]

(pembrolizumab) Injection 100 mg

AVAILABLE
SOON



Dear Customer:

Merck Sharp & Dohme Corp. (Merck), a subsidiary of Merck & Co., Inc., is pleased to announce the availability of a liquid formulation of KEYTRUDA. Merck expects to make this product available on or after February 16, 2015. Check with your authorized distributor for details. This 100-mg liquid vial will replace the 50-mg lyophilized formulation, which was launched as a transition image until the liquid formulation was available. The price per mg has not changed with the introduction of this image.

The 50-mg lyophilized powder formulation will no longer be available from Merck as of February 16, 2015. Please be sure to deplete the 50-mg lyophilized formulation you may have in inventory prior to switching to the 100-mg liquid vial, carton NDC number 0006-3026-02. As a reminder, when billing for the 50-mg lyophilized formulation, please use the carton NDC number 0006-3029-02.

KEYTRUDA will now be supplied as a 100 mg/4 mL (25 mg/mL) solution in a single-use vial.

HOW SUPPLIED	DESCRIPTION	NDC NUMBER	CATALOG PRICE
KEYTRUDA (pembrolizumab) Injection, for intravenous use	Carton containing one 100 mg/4 mL (25 mg/mL), single-use vial	0006-3026-02 The NDC above is the billable NDC that appears on the carton.	\$4,316.00

The following HCPCS^a codes may be used when submitting a claim for KEYTRUDA 100 mg, depending on payer requirements. Please consult with the applicable payer to understand its specific billing requirements. For additional billing and coding information regarding KEYTRUDA, visit merckaccessprogram-keytruda.com.

HCPCS CODE	DESCRIPTOR
J9999	Please refer to the 2015 Alpha-Numeric HCPCS File for a complete description of the code.
J3590	Please refer to the 2015 Alpha-Numeric HCPCS File for a complete description of the code.
J3490	Please refer to the 2015 Alpha-Numeric HCPCS File for a complete description of the code.
C9399 (For use only on Medicare hospital outpatient department claims for dates of service provided before 01/01/2015)	Please refer to the 2015 Alpha-Numeric HCPCS File for a complete description of the code.
C9027 (For use only on Medicare hospital outpatient department claims for dates of service provided on or after 01/01/2015)	Please refer to the 2015 Alpha-Numeric HCPCS File for a complete description of the code.

^aHCPCS=Healthcare Common Procedure Coding System. Source: Centers for Medicare & Medicaid Services; Alpha-Numeric HCPCS.

Information about HCPCS codes is based on guidance issued by the Centers for Medicare & Medicaid Services applicable to Medicare Part B and may not apply to other public or private payers. Consult the relevant manual and/or other guidelines for a description of each code to determine the appropriateness of a particular code and for information on additional codes. You are solely responsible for determining the appropriate codes and for any action you take in billing. The information provided here is not intended to be definitive or exhaustive, and is not intended to replace the guidance of a qualified professional advisor. Merck and its agents make no warranties or guarantees, express or implied, concerning the accuracy or appropriateness of this information for your particular use given the frequent changes in public and private payer billing. The use of this information does not guarantee payment or that any payment received will cover your costs.



KEYTRUDA[®]

(pembrolizumab) Injection 100 mg

AVAILABLE
SOON



DIMENSION/WEIGHT BY CARTON	CASE QUANTITY	DIMENSION/WEIGHT BY CASE	SHIPPING CASE QUANTITY
34.93 x 35.52 x 72.87 mm/ approximately 30 grams	1	6.1" x 9.2" x 6.6"/ approximately 1.5 kilos	48

The Merck Access Program for KEYTRUDA

The Merck Access Program has been designed to provide information that can help answer questions specific to access for KEYTRUDA. The Merck Access Program may be able to answer questions about:

- Insurance coverage for patients
- Billing and coding information
- Co-pay assistance for eligible patients
- Benefit investigations, prior authorizations, and appeals
- Referrals to the Merck Patient Assistance Program
- Product distribution

You can also request to be contacted by a Field Reimbursement Associate.

Distribution of KEYTRUDA

KEYTRUDA is available through authorized distributors. Please contact The Merck Access Program for a list of authorized distributors. Merck does not support the use of any particular distributor, and one is not preferred over the others.

There are 2 easy ways to learn more about The Merck Access Program:
Visit merckaccessprogram-keytruda.com for 24-hour access.
Call **855-257-3932** between 8:00 AM and 8:00 PM ET, Monday through Friday.

If you have any questions regarding KEYTRUDA, please contact your Merck Account Executive.

Sincerely,

Patrick Magri
SVP, Managed Markets and Policy

